ReviewJournal of translational medicine2025
From diagnosis to treatment: exploring the mechanisms underlying optic neuritis in multiple sclerosis.
Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Applications of dynamic gratings in neuro-ophthalmic disorders.Frontiers in medicine · 2026Review
- The Relationship Between OCT and VEP Parameters with Disability and Disease Duration in Relapsing-Remitting Multiple Sclerosis.Diagnostics (Basel, Switzerland) · 2025Article
- Imaging biomarkers in optic neuritis: current tools and future directions.Frontiers in neurology · 2025Review
- System-level hypothesis of dopamine imbalance in early multiple sclerosis.Frontiers in neurology · 2025Article
- Differential diagnosis between NMOSD and MS: a retrospective study based on clinical and imaging features.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system, commonly causing sensory disturbances, motor weakness, impaired gait, incoordination and optic neuritis (ON). According to the statistics, up to 50% of MS patients experience vision problems during the disease course, suffering from blurred vision, pain, color vision deficits, and even blindness. Treatments have progressed from corticosteroids to therapies targeted against B/T cells. This review comprehensively and systematically reappraises the diagnostic methods for visual impairment in MS patients. It also summarizes the most recent treatment approaches and effective medications for ON in MS. Finally, we examine the immunoinflammatory mechanisms that underlie lesions in the central nervous system in multiple sclerosis, in order to direct future investigations to confirm these mechanisms in the visual pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.